Q3 2019 Earnings Forecast for BridgeBio Pharma Issued By Jefferies Financial Group (NASDAQ:BBIO)

Share on StockTwits

BridgeBio Pharma (NASDAQ:BBIO) – Stock analysts at Jefferies Financial Group lowered their Q3 2019 earnings estimates for shares of BridgeBio Pharma in a report issued on Wednesday, August 14th. Jefferies Financial Group analyst E. Yang now anticipates that the company will post earnings of ($0.53) per share for the quarter, down from their previous forecast of ($0.40). Jefferies Financial Group currently has a “Buy” rating and a $38.00 target price on the stock. Jefferies Financial Group also issued estimates for BridgeBio Pharma’s Q4 2019 earnings at ($0.53) EPS, FY2019 earnings at ($2.91) EPS, FY2020 earnings at ($2.01) EPS, FY2021 earnings at ($1.72) EPS, FY2022 earnings at ($2.65) EPS and FY2023 earnings at ($1.85) EPS.

A number of other equities analysts have also commented on the stock. Raymond James began coverage on shares of BridgeBio Pharma in a research report on Friday, July 26th. They issued an “outperform” rating and a $36.00 price target on the stock. Leerink Swann began coverage on shares of BridgeBio Pharma in a research report on Monday, July 22nd. They issued an “outperform” rating and a $34.00 price target on the stock. Goldman Sachs Group began coverage on shares of BridgeBio Pharma in a research report on Monday, July 22nd. They issued a “buy” rating and a $42.00 price target on the stock. BMO Capital Markets began coverage on shares of BridgeBio Pharma in a research report on Monday, July 22nd. They issued an “outperform” rating and a $49.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of BridgeBio Pharma in a research report on Monday, July 22nd. They issued an “overweight” rating and a $38.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $40.13.

Shares of BridgeBio Pharma stock opened at $28.66 on Monday. BridgeBio Pharma has a twelve month low of $24.06 and a twelve month high of $32.81. The company’s 50-day simple moving average is $27.89.

Several hedge funds have recently made changes to their positions in the company. Tiverton Asset Management LLC acquired a new position in shares of BridgeBio Pharma during the second quarter worth approximately $76,000. Point72 Hong Kong Ltd acquired a new position in shares of BridgeBio Pharma during the second quarter worth approximately $255,000. Bank of Montreal Can acquired a new position in shares of BridgeBio Pharma during the second quarter worth approximately $270,000. Point72 Asset Management L.P. acquired a new position in shares of BridgeBio Pharma during the second quarter worth approximately $356,000. Finally, Zimmer Partners LP acquired a new position in shares of BridgeBio Pharma during the second quarter worth approximately $458,000. Institutional investors own 13.17% of the company’s stock.

In other news, major shareholder Genetic Disorder L.P. Kkr purchased 2,647,100 shares of BridgeBio Pharma stock in a transaction on Monday, July 1st. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $45,000,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian C. Stephenson purchased 55,500 shares of BridgeBio Pharma stock in a transaction on Monday, July 1st. The stock was purchased at an average price of $17.00 per share, for a total transaction of $943,500.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 7,408,500 shares of company stock worth $125,944,500.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Further Reading: Special Dividends

Earnings History and Estimates for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VANGUARD SCOTTS/VANGUARD RUSSELL 20  Shares Acquired by Wells Fargo & Company MN
VANGUARD SCOTTS/VANGUARD RUSSELL 20 Shares Acquired by Wells Fargo & Company MN
$1.41 EPS Expected for Burlington Stores Inc  This Quarter
$1.41 EPS Expected for Burlington Stores Inc This Quarter
$1.79 Billion in Sales Expected for Burlington Stores Inc  This Quarter
$1.79 Billion in Sales Expected for Burlington Stores Inc This Quarter
Public Employees Retirement System of Ohio Has $2.94 Million Holdings in Wyndham Destinations
Public Employees Retirement System of Ohio Has $2.94 Million Holdings in Wyndham Destinations
Public Employees Retirement System of Ohio Buys Shares of 34,182 Guardant Health Inc
Public Employees Retirement System of Ohio Buys Shares of 34,182 Guardant Health Inc
Public Employees Retirement System of Ohio Grows Position in Empire State Realty Trust Inc
Public Employees Retirement System of Ohio Grows Position in Empire State Realty Trust Inc


© 2006-2019 Ticker Report